OrSense Overview
OrSense is a medical device company that develops and commercializes noninvasive monitoring technologies for continuous and spot measurements of hemoglobin, oxygen saturation, glucose, and other blood parameters. The companys patented SpectOLight technology, known as occlusion spectroscopy, uses a non-invasive optical measurement platform combined with a finger-attached, ring-shaped sensor probe. The pressure applied by the sensor temporarily occludes the blood flow in the finger, creating new blood dynamics that generate a unique, strong optical signal, yielding a high signal-to-noise ratio that is wholly blood specific. Analysis of the signal provides the sensitivity necessary to measure hemoglobin, pulse rate, oxymetry (even under severe low perfusion levels), and other analyte concentrations.
Cumulative Funding Raised Over Time ($)
$4.0M
$12.2MAug 2001
$19.2MFeb 2004
$25.2MFeb 2006
$43.2MMay 2011
Latest News
growth-positive
FDA Grants Market Clearance for the OrSense NBM200;the First Noninvasive Hemoglobin System Cleared for Use in Blood Donation Centers
OrSense Ltd. has received FDA/CBER 510(K) clearance for its NBM200 non-invasive Hemoglobin measurement device. The clearance allows for the commercialization of the device in all US blood collection centers. The NBM200 is the first non-invasive Hemoglobin measurement device cleared by the FDA/CBER for use in blood banks. It has been used worldwide since 2014 and in the US for over two years by OneBlood. The device provides painless and efficient hemoglobin measurements, eliminating the need for traditional finger pricks. This clearance is expected to improve the blood donor experience and make operations more efficient for blood collection centers.
CustomersPartners
growth-positive
OrSense Delivers First Systems in Mexico
OrSense Ltd. announces the first delivery of its non-invasive Hemoglobin testing systems in Mexico. The NBM200 offers accurate and painless Hb measurements on location, reducing infection risk and environmental impact. OrSense is working closely with Falcón, its distributor in Mexico, to expand its presence in the Mexican market.
Customers
growth-positive
Non-invasive monitoring co OrSense raises $18m
OrSense, a company that develops monitors for non-invasive measurements of key blood parameters, has completed an $18 million financing round led by Israel Healthcare Ventures(IHCV). The funds raised will be used to expand commercialization activities and establish OrSense as the world leader in non-invasive monitoring. OrSense has received FDA clearance for its non-invasive multi-parameter monitor for oxygen saturation and CE approval for the first non-invasive spot and continuous monitor of hemoglobin. The companys customers include blood donation facilities, hospital departments, public screening programs, and outpatient facilities. OrSenses devices have been tested on 8000 subjects in over 40 clinical trials. The investment highlights the continuous support and confidence of the investors.
InvestmentExpand
growth-positive
OrSense completes $6m private financing
OrSense Ltd., a medical device start-up, has received an additional $6 million in funding from investors, including Israel Healthcare Ventures (IHCV), STAR Ventures, and Lewis Trust Group (LTG). The funding will help OrSense establish itself as a world leader in non-invasive glucose monitoring. Carlo Salvi, a director at Teva Pharmaceutical Industries Ltd., has been appointed to OrSenses board of directors. OrSense aims to bring non-invasive glucose monitoring products to the market, reducing the need for needle-stick blood tests. The companys intellectual property portfolio includes 18 granted patents and over 25 additional applications in process. The article was published on February 6, 2006.
Investment
growth-positive
Blood sugar monitor maker OrSense raises $7 million
OrSense, a company that develops noninvasive systems to measure cholesterol, hemoglobin, and glucose in the blood, has raised $7 million in funding. The companys product, the Occlusion Spectroscopy device, is of particular interest to diabetics as it eliminates the need for finger pricking to track blood sugar levels. OrSense has achieved a CE Mark for its product in Europe and is in late stages of clinical trials for FDA approval in the U.S. The company was founded in 1996 and has raised a total of $13 million in funding. It currently has 24 employees.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $44.4M |
| Last funding | $18M |
| Stage | Mature |
| Rounds | 6 |
| Investors | 3 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | orsense.com |
Locations
Ha-Mefalsim Street 17, Petach Tikva, Israel
10900 World Trade Blvd, Raleigh, NC 27617, United States
Photos & Videos
2 item(s)
OrSense Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical MonitorsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
SensingOpticPlatforms & InterfacesSoftwareTags (12)
spectroscopysensorsmeasurementsdiabetesmonitoringhospitalsmedical-devicesnon-invasivehealthcare-providerssoftware-applicationsoptronicsmedical-technologiesGeographic Markets
MexicoUnited StatesEuropeOrSense Financials
$44.4M
Total funding
Undisclosed
Capital raised
$18M
Last funding
Mature
Funding stage
6
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$4.0M
$12.2MAug 2001
$19.2MFeb 2004
$25.2MFeb 2006
$43.2MMay 2011
Private Equity Funding
E Round
May 2011
$18M
Lewis Trust Group, Israel HealthCare Ventures, Star Ventures
D Round
Feb 2006
$6M
Lewis Trust Group, Israel HealthCare Ventures, Star Ventures
C Round
Feb 2004
$7M
B Round
Aug 2001
$8.2M
Israel HealthCare Ventures, Star Ventures
A Round
$4M
Non-Equity Funding
GrantEvent
Aug 2001
$1.2M
Office of the Chief Scientist
OrSense Lifecycle
Cumulative Funding Raised Over Time
$4.0M
$12.2MAug 2001
$19.2MFeb 2004
$25.2MFeb 2006
$43.2MMay 2011
All Events
E Round
May 2011
$18M
Lewis Trust Group, Israel HealthCare Ventures, Star Ventures
D Round
Feb 2006
$6M
Lewis Trust Group, Israel HealthCare Ventures, Star Ventures
C Round
Feb 2004
$7M
B Round
Aug 2001
$8.2M
Israel HealthCare Ventures, Star Ventures
A Round
$4M
GrantEvent
Aug 2001
$1.2M
Office of the Chief Scientist
OrSense News
6 articles
growth-positive
FDA Grants Market Clearance for the OrSense NBM200;the First Noninvasive Hemoglobin System Cleared for Use in Blood Donation Centers
OrSense Ltd. has received FDA/CBER 510(K) clearance for its NBM200 non-invasive Hemoglobin measurement device. The clearance allows for the commercialization of the device in all US blood collection centers. The NBM200 is the first non-invasive Hemoglobin measurement device cleared by the FDA/CBER for use in blood banks. It has been used worldwide since 2014 and in the US for over two years by OneBlood. The device provides painless and efficient hemoglobin measurements, eliminating the need for traditional finger pricks. This clearance is expected to improve the blood donor experience and make operations more efficient for blood collection centers.
CustomersPartners
growth-positive
OrSense Delivers First Systems in Mexico
OrSense Ltd. announces the first delivery of its non-invasive Hemoglobin testing systems in Mexico. The NBM200 offers accurate and painless Hb measurements on location, reducing infection risk and environmental impact. OrSense is working closely with Falcón, its distributor in Mexico, to expand its presence in the Mexican market.
Customers
growth-positive
Non-invasive monitoring co OrSense raises $18m
OrSense, a company that develops monitors for non-invasive measurements of key blood parameters, has completed an $18 million financing round led by Israel Healthcare Ventures(IHCV). The funds raised will be used to expand commercialization activities and establish OrSense as the world leader in non-invasive monitoring. OrSense has received FDA clearance for its non-invasive multi-parameter monitor for oxygen saturation and CE approval for the first non-invasive spot and continuous monitor of hemoglobin. The companys customers include blood donation facilities, hospital departments, public screening programs, and outpatient facilities. OrSenses devices have been tested on 8000 subjects in over 40 clinical trials. The investment highlights the continuous support and confidence of the investors.
InvestmentExpand
growth-positive
OrSense completes $6m private financing
OrSense Ltd., a medical device start-up, has received an additional $6 million in funding from investors, including Israel Healthcare Ventures (IHCV), STAR Ventures, and Lewis Trust Group (LTG). The funding will help OrSense establish itself as a world leader in non-invasive glucose monitoring. Carlo Salvi, a director at Teva Pharmaceutical Industries Ltd., has been appointed to OrSenses board of directors. OrSense aims to bring non-invasive glucose monitoring products to the market, reducing the need for needle-stick blood tests. The companys intellectual property portfolio includes 18 granted patents and over 25 additional applications in process. The article was published on February 6, 2006.
Investment
growth-positive
Blood sugar monitor maker OrSense raises $7 million
OrSense, a company that develops noninvasive systems to measure cholesterol, hemoglobin, and glucose in the blood, has raised $7 million in funding. The companys product, the Occlusion Spectroscopy device, is of particular interest to diabetics as it eliminates the need for finger pricking to track blood sugar levels. OrSense has achieved a CE Mark for its product in Europe and is in late stages of clinical trials for FDA approval in the U.S. The company was founded in 1996 and has raised a total of $13 million in funding. It currently has 24 employees.
InvestmentExpand
growth-positive
OrSense raises $8.2 mln from VC funds
OrSense, an Israeli medical device company, has completed an $8.2 million venture capital financing round. The company was also awarded a $1.2 million grant by the Office of the Chief Scientist. OrSense is developing a non-invasive glucose monitor for daily use by diabetics. The financing round reflects the substantial commitment and support of investors in the company. OrSense aims to bring to market the first truly non-invasive sensor of its kind, targeting a market estimated at $3.5 billion per year.
Investment
Employee Info
| Employees (range) | 11-50 |
| Exact count | 23 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
OrSense Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 512389214 |
| Crunchbase | orsense |
| Phone | +97237404900 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-04-20T00:00:00.000Z |
| Created | 2014-07-08T00:00:00.000Z |